Inicio・Lista de Acciones・Xencor Inc

Xencor Inc

Abierto

SectorSanidad

19.3 -4.27

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

19.24

Máximo

20.58

Métricas clave
By Trading Economics
Ingresos	-214M -129M
Ventas	-24M 4.5M
BPA	-1.71
Margen de beneficios	-2,854.65
Empleados	260
EBITDA	-127M -121M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+17.85% upside

Dividendos
By Acuity
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	404M 1.4B
Apertura anterior	23.57
Cierre anterior	19.3

Noticias sobre sentimiento de mercado

By Acuity

50%

145 / 340 Clasificación en Healthcare

Xencor Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20 jul 2026, 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Comparación entre iguales

Cambio de precio

Xencor Inc previsión

Precio Objetivo

By TipRanks

17.85% repunte

Estimación a 12 Meses

Media 24.1 USD 17.85%

Máximo 38 USD

Mínimo 13 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xencor Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Xencor Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

145 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.